The clinical trials with an agent like this are pretty straightforward and the Advisory Committee agreed that, in terms of clinical efficacy, degludec meets the guidelines for approval.
The Wall Street Journal indicates many businesses want liability protection against attacks in exchange for following the guidelines, which would require approval form Congress in order to happen.